Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Epizyme Inc (NASDAQ:EPZM)

7.70
Delayed Data
As of Aug 26
 +0.16 / +2.12%
Today’s Change
7.36
Today|||52-Week Range
21.28
-51.94%
Year-to-Date
Epizyme Doses First Patient in Phase II Mesothelioma Study
Aug 15 / Zacks.com - Paid Partner Content